Loading...
The 2023 American Society of Clinical Oncology (ASCO) annual meeting, held June 2 to 6 in Chicago, highlighted important advances in treatment across a broad spectrum of malignancies. Here, Associate Editor Dr. Robert Dreicer reviews several key trials in in prostate and renal cancers.
For men with de novo metastatic, castration-sensitive prostate cancer and a low metastatic burden, adding radiotherapy to standard-of-care treatment (defined as androgen-deprivation therapy plus docetaxel) plus abiraterone acetate and prednisone (AAP) was associated with significantly improved progression-free survival (PFS) — but not overall survival (OS) — according to f…